{"resourceType":"Evidence","id":"example-stroke-no-alteplase-fatalICH","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \n      \u003cp\u003e\n        \u0026quot;Risk of fatal ICH without alteplase for stroke\u0026quot; is a univariate risk estimate.\n      \u003c/p\u003e\n\t\n    \u003c/div\u003e"},"url":"http://hl7.org/fhir/Evidence/example-stroke-no-alteplase-fatalICH","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.10.4"}],"name":"RiskOfFatalICHWithoutAlteplaseForStroke","title":"Risk of fatal ICH without alteplase for stroke","status":"draft","relatedArtifact":[{"type":"citation","label":"Emberson 2014","display":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.","citation":"Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al;Stroke Thrombolysis Trialists\u0027 Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014 Nov 29;384(9958):1929-35 PMID 25106063","document":{"url":"https://doi.org/10.1016/S0140-6736(14)60584-5"}}],"description":"0.4% incidence of fatal intracranial hemorrhage within 7 days without alteplase in patients with acute ischemic stroke","variableDefinition":[{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"population","display":"population"}]},"observed":{"reference":"Group/AcuteIschemicStroke","type":"Group","display":"adults with acute ischemic stroke"},"intended":{"reference":"Group/AcuteIschemicStroke","type":"Group","display":"adults with acute ischemic stroke"}},{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"population","display":"population"}]},"observed":{"reference":"Group/Emberson-2014-IPD-MA-No-Alteplase-Cohort","type":"Group","display":"Emberson 2014 IPD-MA No Alteplase Cohort"},"intended":{"reference":"Group/AcuteIschemicStrokeTreatedWithoutAlteplase","type":"Group","display":"adults with acute ischemic stroke treated without alteplase"}},{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"measuredVariable","display":"measured variable"}]},"observed":{"reference":"EvidenceVariable/example-fatal-ICH-in-7-days","type":"EvidenceVariable","display":"fatal ICH"},"intended":{"reference":"EvidenceVariable/example-fatal-ICH-in-7-days","type":"EvidenceVariable","display":"fatal ICH"}}],"synthesisType":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/synthesis-type","code":"IPD-MA","display":"individual patient data meta-analysis"}]},"studyDesign":[{"coding":[{"system":"http://hl7.org/fhir/study-design","code":"SEVCO:01003","display":"randomized assignment"}]}],"statistic":[{"statisticType":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/statistic-type","code":"C44256","display":"Proportion"}]},"quantity":{"value":0.00386298627},"numberOfEvents":13,"sampleSize":{"numberOfStudies":9,"numberOfParticipants":3365}}]}
{"resourceType":"Evidence","id":"example-stroke-3-4half-alteplase-vs-no-alteplase-mRS0-2","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \n      \u003cp\u003e\n        \u0026quot;Effect of Alteplase vs No alteplase on mRS 0-2 at 90 days in Stroke 3-4.5 hours prior\u0026quot; is a comparative effect estimate.\n      \u003c/p\u003e\n\t\n    \u003c/div\u003e"},"url":"http://hl7.org/fhir/Evidence/example-stroke-3-4half-alteplase-vs-no-alteplase-mRS0-2","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.10.3"}],"name":"EffectOfAlteplaseVsNoAlteplaseOnMRS02At90DaysInStroke345HoursPrior","title":"Effect of Alteplase vs No alteplase on mRS 0-2 at 90 days in Stroke 3-4.5 hours prior","status":"draft","relatedArtifact":[{"type":"citation","label":"Lees 2016","display":"Figure 2 Lees 2016","citation":"Lees KR, Emberson J, Blackwell L, Bluhmki E, Davis SM, Donnan GA, et al; Stroke Thrombolysis Trialists’ Collaborators Group. Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. Stroke. 2016;47:2373-2379. PMID 27507856","document":{"url":"https://doi.org/10.1161/STROKEAHA.116.013644"}}],"description":"mRS 0-2 at 90 days Odds Ratio 1.2 for Alteplase vs. No Alteplase in patients with acute ischemic stroke 3-4.5 hours prior","variableDefinition":[{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"population","display":"population"}]},"observed":{"reference":"EvidenceVariable/Stroke-Thrombolysis-Trialists-2014-2016-IPD-MA-Cohort","type":"EvidenceVariable","display":"Stroke Thrombolysis Trialists’ 2014-2016 IPD-MA Cohort"},"intended":{"reference":"Group/AcuteIschemicStroke3-4halfHours","type":"Group","display":"stroke at 3-4.5 hours"},"directnessMatch":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/directness","code":"moderate","display":"Moderate quality match"}]}},{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"measuredVariable","display":"measured variable"}]},"observed":{"reference":"EvidenceVariable/example-mRS0-2-at-90days","type":"EvidenceVariable","display":"mRS 0-2 at 90 days"},"intended":{"reference":"EvidenceVariable/example-alive-independent-90day","type":"EvidenceVariable","display":"Alive and not functionally dependent at 90 days"}},{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"exposure","display":"exposure"}]},"observed":{"reference":"EvidenceVariable/example-alteplase-for-stroke","type":"EvidenceVariable","display":"Alteplase for Stroke"},"intended":{"reference":"EvidenceVariable/example-alteplase-for-stroke","type":"EvidenceVariable","display":"Alteplase for Stroke"}},{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"referenceExposure","display":"reference exposure"}]},"observed":{"reference":"EvidenceVariable/example-no-alteplase","type":"EvidenceVariable","display":"no alteplase"},"intended":{"reference":"EvidenceVariable/example-no-alteplase","type":"EvidenceVariable","display":"no alteplase"}}],"synthesisType":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/synthesis-type","code":"IPD-MA","display":"individual patient data meta-analysis"}]},"studyDesign":[{"coding":[{"system":"http://hl7.org/fhir/study-design","code":"SEVCO:01003","display":"randomized assignment"}]}],"statistic":[{"statisticType":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/statistic-type","code":"C16932","display":"Odds Ratio"}]},"quantity":{"value":1.2},"sampleSize":{"numberOfStudies":9},"attributeEstimate":[{"description":"95% CI 1.06 to 1.3","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/attribute-estimate-type","code":"C53324","display":"Confidence interval"}]},"level":0.95,"range":{"low":{"value":1.06},"high":{"value":1.3}}}]}],"certainty":[{"description":"Very low certainty due to risk of bias, inconsistency, imprecision, and indirectness","type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Overall","display":"Overall quality"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"very-low","display":"Very low quality"}]},"subcomponent":[{"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"PublicationBias","display":"Publication bias"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"note":[{"text":"IST-3 had inconsistent results and contributed large proportion of data"}],"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Inconsistency","display":"Inconsistency"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"serious-concern","display":"serious concern"}]}},{"note":[{"text":"results derived from figure with limited data reported to support the specific effect estimate; derived odds ratio in figure does not match results from rates of mRS 0-2 reported in Supplementary Figure 3b"}],"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Imprecision","display":"Imprecision"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"serious-concern","display":"serious concern"}]}},{"note":[{"text":"resuts derived for 3 - 4.5 hours assume data from 0 - 6 hours is informative"}],"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Indirectness","display":"Indirectness"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"serious-concern","display":"serious concern"}]}},{"note":[{"text":"results largely influenced by IST-3 trial which was unblinded and ECASS III which had baseline imbalances"}],"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"RiskOfBias","display":"Risk of bias"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"serious-concern","display":"serious concern"}]}}]}]}
{"resourceType":"Evidence","id":"example-stroke-0-3-alteplase-vs-no-alteplase-mRS3-6","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \n      \u003cp\u003e\n        \u0026quot;Effect of Alteplase vs No alteplase on mRS 3-6 at 90 days in Stroke 0-3 hours prior\u0026quot; is a comparative effect estimate.\n      \u003c/p\u003e\n\t\n    \u003c/div\u003e"},"url":"http://hl7.org/fhir/Evidence/example-stroke-0-3-alteplase-vs-no-alteplase-mRS3-6","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.10.5"}],"name":"EffectOfAlteplaseVsNoAlteplaseOnMRS36At90DaysInStroke03HoursPrior","title":"Effect of Alteplase vs No alteplase on mRS 3-6 at 90 days in Stroke 0-3 hours prior","status":"draft","relatedArtifact":[{"type":"citation","label":"Wardlaw 2014","display":"Analysis 1.16 from Wardlaw 2014","citation":"Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014 Jul 29(7):CD000213. PMID 25072528","document":{"url":"https://doi.org/10.1002/14651858.CD000213.pub3"}}],"description":"mRS 3-6 at 90 days Odds Ratio 0.65 for Alteplase vs. No Alteplase in patients with acute ischemic stroke 0-3 hours prior","variableDefinition":[{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"population","display":"population"}]},"observed":{"reference":"EvidenceVariable/Wardlaw2014Analysis1.16.3EvidenceSet","type":"EvidenceVariable","display":"Wardlaw 2014 Analysis 1.16.3 Evidence set"},"intended":{"reference":"Group/AcuteIschemicStroke0-3Hours","type":"Group","display":"stroke at 0-3 hours"}},{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"measuredVariable","display":"measured variable"}]},"observed":{"reference":"EvidenceVariable/example-mRS3-6-at-90days","type":"EvidenceVariable","display":"mRS 3-6 at 90 days"},"intended":{"reference":"EvidenceVariable/example-dead-or-dependent-90day","type":"EvidenceVariable","display":"Dead or functionally dependent at 90 days"}},{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"exposure","display":"exposure"}]},"observed":{"reference":"EvidenceVariable/example-alteplase-for-stroke","type":"EvidenceVariable","display":"Alteplase for Stroke"},"intended":{"reference":"EvidenceVariable/example-alteplase-for-stroke","type":"EvidenceVariable","display":"Alteplase for Stroke"}},{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"referenceExposure","display":"reference exposure"}]},"observed":{"reference":"EvidenceVariable/example-no-alteplase","type":"EvidenceVariable","display":"no alteplase"},"intended":{"reference":"EvidenceVariable/example-no-alteplase","type":"EvidenceVariable","display":"no alteplase"}}],"synthesisType":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/synthesis-type","code":"std-MA","display":"summary data meta-analysis"}]},"studyDesign":[{"coding":[{"system":"http://hl7.org/fhir/study-design","code":"SEVCO:01003","display":"randomized assignment"}]}],"statistic":[{"statisticType":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/statistic-type","code":"C16932","display":"Odds Ratio"}]},"quantity":{"value":0.65},"numberOfEvents":1137,"sampleSize":{"numberOfStudies":6,"numberOfParticipants":1779},"attributeEstimate":[{"description":"95% CI 0.54 to 0.80","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/attribute-estimate-type","code":"C53324","display":"Confidence interval"}]},"level":0.95,"range":{"low":{"value":0.54},"high":{"value":0.8}}},{"description":"P-value \u003d 0.000023","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/attribute-estimate-type","code":"C44185","display":"P-value"}]},"quantity":{"value":0.000023}},{"description":"Heterogeneity I-sq \u003d 0.0%","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/attribute-estimate-type","code":"0000420","display":"I-squared"}]},"quantity":{"value":0,"unit":"%","system":"http://unitsofmeasure.org","code":"%"}}]}],"certainty":[{"description":"Moderate certainty due to risk of bias","type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Overall","display":"Overall quality"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"moderate","display":"Moderate"}]},"subcomponent":[{"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"PublicationBias","display":"Publication bias"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Inconsistency","display":"Inconsistency"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Imprecision","display":"Imprecision"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Indirectness","display":"Indirectness"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"note":[{"text":"results largely influenced by IST-3 trial which was unblinded and NINDS trial which had allocation concealment not stated and baseline imbalances"}],"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"RiskOfBias","display":"Risk of bias"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"serious-concern","display":"serious concern"}]}}]}]}
{"resourceType":"Evidence","id":"example-stroke-alteplase-fatalICH","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \n      \u003cp\u003e\n        \u0026quot;Risk of fatal ICH with alteplase for stroke\u0026quot; is a univariate risk estimate.\n      \u003c/p\u003e\n\t\n    \u003c/div\u003e"},"url":"http://hl7.org/fhir/Evidence/example-stroke-alteplase-fatalICH","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.10.1"}],"name":"RiskOfFatalICHWithAlteplaseForStroke","title":"Risk of fatal ICH with alteplase for stroke","status":"draft","relatedArtifact":[{"type":"citation","label":"Emberson 2014","display":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.","citation":"Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al;Stroke Thrombolysis Trialists\u0027 Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014 Nov 29;384(9958):1929-35 PMID 25106063","document":{"url":"https://doi.org/10.1016/S0140-6736(14)60584-5"}}],"description":"2.7% incidence of fatal intracranial hemorrhage within 7 days with alteplase in patients with acute ischemic stroke","variableDefinition":[{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"population","display":"population"}]},"observed":{"reference":"Group/AcuteIschemicStroke","type":"Group","display":"adults with acute ischemic stroke"},"intended":{"reference":"Group/AcuteIschemicStroke","type":"Group","display":"adults with acute ischemic stroke"}},{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"population","display":"population"}]},"observed":{"reference":"Group/Emberson-2014-IPD-MA-Alteplase-Cohort","type":"Group","display":"Emberson 2014 IPD-MA Alteplase Cohort"},"intended":{"reference":"Group/AcuteIschemicStrokeTreatedWithAlteplase","type":"Group","display":"adults with acute ischemic stroke treated with alteplase"}},{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"measuredVariable","display":"measured variable"}]},"observed":{"reference":"EvidenceVariable/example-fatal-ICH-in-7-days","type":"EvidenceVariable","display":"fatal ICH"},"intended":{"reference":"EvidenceVariable/example-fatal-ICH-in-7-days","type":"EvidenceVariable","display":"fatal ICH"}}],"synthesisType":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/synthesis-type","code":"IPD-MA","display":"individual patient data meta-analysis"}]},"studyDesign":[{"coding":[{"system":"http://hl7.org/fhir/study-design","code":"SEVCO:01003","display":"randomized assignment"}]}],"statistic":[{"statisticType":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/statistic-type","code":"C44256","display":"Proportion"}]},"quantity":{"value":0.026835741669},"numberOfEvents":91,"sampleSize":{"numberOfStudies":9,"numberOfParticipants":3391}}]}
{"resourceType":"Evidence","id":"example-ASTRAL-12-alteplase-mRS3-6","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \n      \u003cp\u003e\n        \u0026quot;Risk of mRS3-6 at 90 days after Alteplase for Stroke if ASTRAL score 12\u0026quot; is a univariate risk estimate.\n      \u003c/p\u003e\n\t\n    \u003c/div\u003e"},"url":"http://hl7.org/fhir/Evidence/example-ASTRAL-12-alteplase-mRS3-6","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.10.2"}],"name":"RiskOfMRS36At90DaysAfterAlteplaseForStrokeIfASTRALScore12","title":"Risk of mRS3-6 at 90 days after Alteplase for Stroke if ASTRAL score 12","status":"draft","relatedArtifact":[{"type":"citation","label":"Cooray 2016 Validation Study","display":"External Validation of the ASTRAL and DRAGON Scores for Prediction of Functional Outcome in Stroke.","citation":"Cooray C, Mazya M, Bottai M, Dorado L, Skoda O, Toni D, Ford GA, Wahlgren N, Ahmed N. External Validation of the ASTRAL and DRAGON Scores for Prediction of Functional Outcome in Stroke. Stroke. 2016 Jun;47(6):1493-9. Epub 2016 May 12. PMID 27174528","document":{"url":"https://doi.org/10.1161/STROKEAHA.116.012802"}}],"description":"5.3% risk of mRS 3-6 at 90 days","variableDefinition":[{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"population","display":"population"}]},"observed":{"reference":"Group/ASTRAL-Cooray-validation-cohort","type":"Group","display":"ASTRAL validation cohort"},"intended":{"reference":"Group/ASTRAL-12","type":"Group","display":"patients 0-4.5 hours after acute ischemic stroke onset with ASTRAL score \u003d 12"}},{"description":"functionally dependent or dead at 3 months","variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"measuredVariable","display":"measured variable"}]},"observed":{"reference":"EvidenceVariable/example-mRS3-6-at-90days","type":"EvidenceVariable","display":"mRS 3-6 at 90 days"},"intended":{"reference":"EvidenceVariable/example-dead-or-dependent-90day","type":"EvidenceVariable","display":"Dead or functionally dependent at 90 days"},"directnessMatch":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/directness","code":"high","display":"High quality match"}]}},{"variableRole":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/variable-role","code":"exposure","display":"exposure"}]},"observed":{"reference":"EvidenceVariable/example-alteplase-for-stroke","type":"EvidenceVariable","display":"Alteplase for Stroke"},"intended":{"reference":"EvidenceVariable/example-alteplase-for-stroke","type":"EvidenceVariable","display":"Alteplase for Stroke"},"directnessMatch":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/directness","code":"exact","display":"Exact match"}]}}],"studyDesign":[{"coding":[{"system":"http://hl7.org/fhir/study-design","code":"SEVCO:01016","display":"Uncontrolled cohort design"}]}],"statistic":[{"description":"5.3% risk","statisticType":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/statistic-type","code":"C44256","display":"Proportion"}],"text":"derived proportion"},"quantity":{"value":0.0525},"sampleSize":{"note":[{"text":"number of participants describes number in the total study sample, known data count describes number in study sample with ASTRALscore \u003d 12, total number of events describes number of participants with ASTRAL score \u003d 12 and outcome of mRS 3-6 at 90 days"}],"numberOfParticipants":36131}}],"certainty":[{"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Overall","display":"Overall quality"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"high","display":"High quality"}]},"subcomponent":[{"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"RiskOfBias","display":"Risk of bias"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"description":"Estimated risk from validation calibration plot consistent with predicted risk; observed risk in subgroup with ASTRAL score \u003d 12 consistent with validation calibration plot","type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Inconsistency","display":"Inconsistency"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Indirectness","display":"Indirectness"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"description":"Narrow confidence interval","type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"Imprecision","display":"Imprecision"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"type":{"coding":[{"system":"http://hl7.org/fhir/certainty-type","code":"PublicationBias","display":"Publication bias"}]},"rating":{"coding":[{"system":"http://hl7.org/fhir/certainty-rating","code":"no-concern","display":"no serious concern"}]}}]}]}